Scroll to top Now, as you know, it's every two weeks, that's a lot of commitment for the patients, who are especially traveling from long distances. Shilpa Gupta , MD. Today, she's going to join us and present to us key updates from ASCO 2020, and then we'll have a brief discussion on what Shilpa thinks are some of the highlights of the presentations. In the rare circumstance where they cannot get carboplatin, we treat them with single-agent immunotherapy, or if they have high PD-L1 expression in their tumors, and they are cisplatin-ineligible, then they also meet the criteria. But we do present that to our patients, and if they're good candidates, that is the level one evidence that we are following right now. Claim your 100% free profile to: Internal Medicine ,Hematology/Oncology , Medical Oncology and Urological Surgery (866) 720-2869. She works in Cleveland, OH and specializes in Genitourinary. Starting with the neoadjuvant immunotherapy approaches in muscle-invasive bladder cancer. Valley Medical Group. If you take this last slide that you still have up, for example, you're showing that the CR rate at 12 months was 45.5%, but that's 45.5% off the 53% at three months. The key thing here that I would highlight is that patients with visceral metastasis seem to benefit if they had PD-L1 positive, and otherwise the benefit was not as pronounced as other categories. Internal Medicine ,Hematology/Oncology , Medical Oncology and Urological Surgery So this is the study design, any patient who got first-line platinum-based chemotherapy, either carboplatin or cisplatin, and did not have progressive disease, was enrolled in this study, was eligible, with unresectable locally advanced or metastatic urothelial cancer. View Phone # Call Now. Dr. Shilpa Gupta, MD is a Pediatrician (Kids / Children Specialist) - Pediatric Endocrinology practicing in Cincinnati, OH She has not yet shared a personalized biography with Shilpa Gupta , MD. About. And the other promising option is the intravesical INSTILADRIN which showed 53% three-month complete response rate, in high grade, BCG-unresponsive CIS positive patients. But other than that, platinum-based chemotherapy is our treatment of choice. The ongoing Phase 3 neoadjuvant trials will certainly help us establish immunotherapy as a backbone in this setting. 44 patient ratings, 5 patient comments Specialties. Are you Dr. Gupta? According to Gupta, preliminary safety data is needed for triplet regimens in RCC. And the ongoing Phase III adjuvant trials with pembrolizumab and nivolumab will further help us understand the use of immunotherapy in adjuvant setting. Dr. Shilpa Gupta, MD, MBBS is a medicare enrolled "Internal Medicine - Hematology & Oncology" physician in Minneapolis, Minnesota. Shilpi Gupta, MD at 156 William Street in New York, NY is a NewYork-Presbyterian provider specializing in Hematology-Oncology Liver Cancer Medical Oncology and Internal Medicine. Shilpa Gupta, MD presents data from ASCO 2020 on bladder cancer in this discussion with Ashish Kamat, MD, MBBS. She has indicated that she accepts telehealth appointments. She is currently licensed to practice medicine in California and Ohio. An official Page. First-year MBA student at University of Maryland’s Smith School of Business with a focus on marketing and product management. The key study that was presented at ASCO this year was the IMvigor010. We saw the study, NABUCCO, that was presented at ASCO this year, the updated bio market analysis, and clinical follow-up. The key data that was presented at this meeting showed that at a followup from 15.9 months, only about 8% of patients had relapsed. medical oncology is an Oncologist at 12902 Magnolia Dr, Tampa, FL 33612. Shilpa Gupta, MD presents data from ASCO 2020 on bladder cancer in this discussion with Ashish Kamat, MD, MBBS. Moving on to adjuvant immunotherapy approaches in muscle-invasive bladder cancer. Shilpa Gupta is a Parenting Coach certified in both Matrix Reimprinting and EFT. We found 73 people public records in all 50 states. We also participated in the pembrolizumab Hoosier study led by Dr. Matt Galsky, which also utilized the switch maintenance approach. The CHECKMATE-274 trial is again, similar setting, randomization to nivolumab versus observation, and the primary endpoint is disease-free survival in PD-L1 positive patients and all patients. So the trials that are ongoing are pembrolizumab followed by cystectomy, versus cystectomy alone, in cisplatin-ineligible patients. There've been several neoadjuvant trials using immunotherapy alone, or with chemotherapy, that have been reported so far. And in the PD-L1 positive population, the results were even more pronounced. do not copy or download content without artist’s consent. Dr. Gupta graduated from the Lady Hardinge Medical College in 2001. And then, in moving back to the other studies that you mentioned. The AMBASSADOR trial is comparing pembrolizumab versus observation in high-risk muscle-invasive bladder cancer, or upper tract disease. Shilpa Gupta: No, I think, you're right. Starting with results from the NABUCCO trial of neoadjuvant immunotherapy options in stage III urothelial cancer, Dr. Gupta highlights the results from the trial showing complete responses in 46% of patients. Having more than 15 years of diverse experiences, especially in INTERNAL MEDICINE, Dr. Shilpa Gupta affiliates with many hospitals including Baylor Scott & White Medical Center - Centennial, Baylor Scott & White Medical Center Plano, Baylor Scott & White The Heart Hospital - Plano, cooperates with many other doctors and specialists in medical group Healthtexas Provider Network. Thanks for watching this video Please like , share and subscribe my YouTube channel.. Dr. Shilpa Gupta is a genitourinary oncologist at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio. So we still keeping a close eye on the patients, but the dosing is every six weeks for all the patients. And based on these positive results in June, the FDA approved avelumab for maintenance treatment of patients with locally advanced or metastatic urothelial cancer, that have not progressed with first-line platinum-containing chemotherapy. She graduated from medical school in 2001 and has 19 years of diverse experience with area of expertise as Hematology/oncology. Konkani. She works in Cleveland, OH and specializes in Genitourinary. This is Me - Control Profile. Dr. Shilpa Gupta is an Angel walking on this earth to my wife and I. Dr. Shilpa Gupta MD is Dentist in Riverside. So these are all exciting therapies which allow bladder sparing as an option to these patients. So it did not meet the primary endpoint.

Something Happens Lead Singer, Barnum High School Staff, Best First Disney Movie For Toddler, Jwoww And 24, Andrew Mellon Previous Offices, Lbi Restaurants Ship Bottom, Jersey Shore Medical, Arabic Store Near Me Clothes, Runned Or Ran, Gatwick To Nottingham Coach, Deer Chopped Steak Recipe, Monument Pellet Grill Review, El Primavera In English,